Shares of Hims & Hers Health (NYSE: HIMS) extended their momentum Thursday, climbing about 11% in premarket trading after a
1 day ago
Cocrystal Pharma (NASDAQ: COCP) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its
2 weeks ago
Cyclerion Therapeutics (NASDAQ: CYCN) saw its stock skyrocket on Wednesday, surging more than 300% during regular trading before extending gains
GlucoTrack (NASDAQ: GCTK) has outlined plans to pursue U.S. regulatory clearance for its glucose monitoring device, a development that quickly
3 weeks ago
iTonic Holdings (NASDAQ: ITOC) announced a $20 million private placement deal on Monday, sparking a sharp rally in after-hours trading—even
Scienture Holdings (NASDAQ: SCNX) has secured several group purchasing organization (GPO) agreements that significantly expand institutional access to its overdose
1 month ago
ImmunityBio (NASDAQ: IBRX) unveiled a new international partnership designed to expand global access to its cancer therapy, Anktiva. Specifically, the
2 months ago
Shares of Hims & Hers Health (NYSE: HIMS) plunged nearly 10% in regular trading on Tuesday as investors digested a
Novo Nordisk (NYSE: NVO) said it plans to pursue legal and regulatory action against telehealth provider Hims & Hers Health
UnitedHealth Group shares (NYSE: UNH) plunged after U.S. regulators signaled minimal growth in future Medicare Advantage payments, overshadowing the company’s
3 months ago
Shares of 60 Degrees Pharmaceuticals (NASDAQ: SXTP) jumped 152% Thursday to an intraday 52-week high after the company announced a
RAPT Therapeutics stock (NASDAQ: RAPT) surged 63.86% to $57.52 in morning trading after GSK announced plans to acquire the biotech
